Table 2. Demographic characteristics of the surgical and non-surgical inpatients.
| Surgical Inpatientsa n = 3 486 003 |
Non-surgical Inpatients n = 4 286 047 |
|||||||
|---|---|---|---|---|---|---|---|---|
| Anti-MRSA drug groupb | Control groupc | Mean Differenced | Mean ratioe | Anti-MRSA drug groupb | Control groupc | Mean Differenced | Mean ratioe | |
| Number of hospitals, n | 1085 | 1131 | - | - | 1104 | 1132 | - | - |
| Number of patients, n (%) | 49 787 (1.43) | 1 028 484 (29.5) | - | - | 44 051 (1.03) | 1 153 343 (26.9) | - | - |
| Mean age, years (SD) | 65.6 (20.9) | 64.6 (20.2) | - | - | 68.2 (21.0) | 61.9 (28.4) | - | - |
| Female sex, n (%) | 18 262 (36.7) | 500 009 (47.5) | - | - | 17 317 (39.3) | 526 393 (45.6) | - | - |
| Mean hospitalization costs, US$ (SD) | 41 989 (52 388) | 13 401 (14 803) | 28 588 | 3.26 | 24 007 (36 606) | 7020 (9681) | 16 987 | 3.42 |
| Median hospitalization costs, US$ (IQR) | 29 596 (16 753–49 789) | 8771 (5246–15 581) | - | - | 14 721 (8049–26 079) | 4306 (2606–8154) | - | - |
| Mean length of stay, days (SD) | 86.8 (149) | 27.9 (82.2) | 58.9 | 3.10 | 63.2 (125) | 23.6 (79.7) | 39.6 | 2.68 |
| Median length of stay, days (IQR) | 60 (36–100) | 18 (10–34) | - | - | 43 (24–74) | 14 (8–27) | - | - |
| In-hospital mortality, n (%) | 9471 (19.0) | 33 888 (3.29) | (15.7) | 5.77 | 11 988 (27.2) | 102 607 (8.90) | (18.3) | 3.06 |
SD, Standard Deviation; IQR, Interquartile Range; MRSA, Methicillin-resistant Staphylococcus aureus
a Surgical inpatients: Patients who had undergone surgery during hospitalization
b Anti-MRSA drug group: Patients administered anti-MRSA drugs for four days or more
c Control group: Patients administered antibiotics (excluding anti-MRSA drugs) for four days or more
d Mean difference: Mean outcome value of the anti-MRSA drug group minus the mean outcome value of the control group
e Mean ratio: Mean outcome value of the anti-MRSA drug group divided by the mean outcome value of the control group